On December 12, 2016, Mako Research published a report stating, in part, that Abeona's trial design for the Company's ABO-101 and ABO-102 gene therapy treatments was significantly flawed and scientifically unviable.
On this news, Abeona stock fell $0.70, or 13.59%, to close at $4.45 on December 12, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-abeona-therapeutics-inc-300377503.html
SOURCE Pomerantz LLP